UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
(Mark One)
☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended June 30, 2018
OR
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to .
Commission File Number: 001-38096
G1 THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware | 26- 3648180 |
( State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
|
|
79 T.W. Alexander Drive 4501 Research Commons, Suite 100 Research Triangle Park, NC | 27709 |
(Address of principal executive offices) | (Zip Code) |
Registrant's telephone number, including area code: (919) 213-9835
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer |
| ☐ |
| Accelerated filer |
| ☐ |
Non-accelerated filer |
| ☒ (Do not check if a small reporting company) |
| Small reporting company |
| ☐ |
|
|
|
| Emerging growth Company |
| ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of July 31, 2018, the registrant had 33,404,535 shares of common stock, $0.0001 par value per share, outstanding.
Table of Contents
|
| Page |
PART I. | FINANCIAL INFORMATION | 1 |
Item 1. | Financial Statements (Unaudited) | 1 |
| Condensed Balance Sheets | 1 |
| Condensed Statements of Operations | 2 |
| Condensed Statements of Cash Flows | 3 |
| Notes to Unaudited Condensed Financial Statements | 4 |
Item 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations | 12 |
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 20 |
Item 4. | Controls and Procedures | 20 |
PART II. | OTHER INFORMATION | 22 |
Item 1A. | Risk Factors | 22 |
Item 6. | Exhibits | 23 |
Signatures | 24 | |
i